Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Sep 16, 2025 | Press Releases

First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic...

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Sep 8, 2025 | Press Releases

— Recommendation that trial escalate to next dose level of 8mg tablet — — Initial interim clinical data from first two cohorts expected in Q1 2026 — MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA)...

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

by divibasicbldev | Aug 29, 2025 | Press Releases

MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced...

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

by divibasicbldev | Aug 28, 2025 | Press Releases

MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced...

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Jul 31, 2025 | Press Releases

– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 -MIAMI, July 31, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage...